Kornimate/medical-research-clean huggingface dataset:
irritable bowel syndrome and low fodmap diet

Conditions: Irritable Bowel Syndrome

Summary: the patients having a syndrome sii would be more intolerant in the fructose than the healthy subjects and would benefit from a fructose diet but also from the fructans which contain some fructose. the intolerance in the fructose is diagnosed thanks to a respiratory test after absorption of fructose. however, the eviction of the fructose is sometimes recommended to the patients without having realized beforehand the test of intolerance.

the main objective is to evaluate the efficacy of the fodmaps diet on ibs symptoms and to correlate the results with the respiratory test

Eligibility criteria:
inclusion criteria: * older than 18, patients with ibs, patients with no organic disorders, patients informed and agreed to participate exclusion criteria: * patients with sclerodermia, diabetes, obesity, anorexia, colo-rectal surgery, patients with small intestinal bacterial overgrowth, pregnancy

Keywords: fructose test
comprehensive management for the treatment of obstructive sleep apnea

Conditions: SLEEP APNEA SYNDROME

Summary: study objetives : the aim of this study is to assess the impact of a combined therapy treatment (physical exercise, oropharyngeal exercises and dietary recommendations) on symptoms and quality of life in patients with osas, as an alternative or addition to therapeutic treatment with nocturnal cpap.

the obstructive sleep apnea syndrome (osas) is characterized by repetitive obstruction of the upper airway during sleep. osas is associated with a wide range of health consequences such as daytime sleepiness, cognitive impairment and metabolic and cardiovascular diseases. in spain the prevalence of this disease is 3 to 6%, constituting a public health problem. the recommended first line treatment for osas is continuous positive pressure airway (cpap). physical exercise has been shown to ameliorate the consequences of osas such as cardiovascular disease, glucose intolerance and fatigue. scientific studies have shown that vigorous physical activity is associated with a decrease in the prevalence of osas, improved sleep efficiency and the epworth sleepiness scale. moreover, recent evidence has shown that oropharyngeal exercises can be useful in the treatment of osas decreasing neck circumference, snoring, subjective sleepiness and ahi as well as improving the quality of life and saturation oxygen. the 60-70% of patients with osas is overweight or obese showing that a high body mass index (bmi) is an independent risk factor for the occurrence of osas. many studies have shown that weight loss is associated with significant reduction in ahi. however, despite the scientific evidence to justify the inclusion of these modalities, there is no study that has analyzed the impact of performing together all these interventions. it is expected that the combination can produce a cumulative effect that impacts significantly on improving indicators of osas. the investigators will include patients with a recent diagnosis of moderate or severe osa. patients will be randomized to interventional or control group. patients included in the study will be followed for almost three months and they will be examined at baseline and after time of follow-up or intervention.

Eligibility criteria:
inclusion criteria: * moderate to severe obstructive sleep apnea hypopnea syndrome (ahi \> 15/h) exclusion criteria: * bmi \> 40 * concomitant heart disease, stroke or severe neuromuscular with medical judgment not doing exercise. * musculoskeletal disorders that impede the realization of the exercises * sleepiness affects your physical or occupational functioning.

Keywords: sleep apnea exercise
clinical study to assess the tolerability, feasibility and effectiveness of nifurtimox and eflornithine (nect) for the treatment of trypanosoma brucei gambiense human african trypanosomiasis (hat) in the meningo-encephalitic phase

Conditions: Human African Trypanosomiasis

Summary: multicenter, open label, uncontrolled phase iiib study of therapeutic use of the combination of nifurtimox and eflornithine (nect) for the treatment of trypanosoma brucei gambiense human african trypanosomiasis (hat) in the meningo-encephalitic phase. overall objectives: assess the clinical tolerability, feasibility and effectiveness of nect co-administration to treat patients with t.b. gambiense human african trypanosomiasis (hat) in the meningo-encephalitic phase in actual real-life conditions (regular treatment centers of the national hat control programme, ngo treatment centers). primary objective: * assess the clinical response of the nect co-administration under field conditions. secondary objectives: * assess the incidence and type of adverse events (ae), and the capacity of the treatment centers to deal with these. * assess the feasibility of the implementation of the nect coadministration by the health center. * assess the effectiveness of the nect co-administration at 24\* months after treatment.


Eligibility criteria:
inclusion criteria: all patients diagnosed as stage 2 hat according to the diagnostic protocols in use at the treatment center (generally, if presence of parasites in blood, lymph node fluid or csf and an elevated white blood cell count in the csf, but this can vary from center to center) will be included if a written informed consent is given by the patient or a legally acceptable representative if the patient is a minor or unable to communicate. * pregnancy and breastfeeding women: on a case by case basis according to the guidelines of the national hat control programme or the ngo, the investigator will decide to treat the patient or to defer the treatment. in case of inclusion, the mother-child pairs or the children of lactating mothers will be closely monitored during treatment and follow up. * children under 2 years of age: on a case by case basis, the investigator will decide to treat an infant with nect or an alternative treatment (preferably eflornithine). in case of inclusion, these infants will be closely monitored during treatment and follow up like all children less than 12 years of age. exclusion criteria: * unable to take oral medication, and impossibility to use a nasogastric tube. * treatment failure after nifurtimox-eflornithine treatment. * any other condition or reason for which the investigator (or the responsible treating staff member) judges that another or no hat treatment is warranted.

Keywords: human african trypanosomiasis hat sleeping sickness combination treatment nifurtimox eflornithine human african trypanosomiasis in the meningo-encephalitic phase (stage 2 hat)
different cycles of high-dose dexamethasone for initial management of primary immune thrombocytopenia (itp)

Conditions: Immune Thrombocytopenia

Summary: the project was organized by qilu hospital of shandong university in china. in order to report the efficacy and safety of different cycles of high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (itp).

the investigators are undertaking a multicenter, randomized, controlled trial of 200 primary itp adult patients from 11 medical centers in china. one part of the participants are randomly selected to receive four cycles of high-dose dexamethasone (given orally at a dose of 40mg per day for 4 consecutive days every 14 days for 4 cycles), comparing the others with one cycle (given orally at a dose of 40 mg per day for 4 consecutive days). platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study. in order to report the efficacy and safety of different cycles of high-dose dexamethasone therapy for the treatment of adults with itp.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria for immune thrombocytopenia. 2. untreated hospitalized patients, may be male or female, between the ages of 18 \~ 80 years. 3. to show a platelet count \<30 \* 10\^9/l, and with bleeding manifestations. 4. willing and able to sign written informed consent. exclusion criteria: 1. received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit. 2. received second-line itp-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit. 3. received high-dose steroids or ivig in the 3 weeks prior to the start of the study. 4. current hiv infection or hepatitis b virus or hepatitis c virus infections. 5. severe medical condition (lung, hepatic or renal disorder) other than chronic itp. unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 6. female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period. 7. have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test. 8. patients who are deemed unsuitable for the study by the investigator.

Keywords: itp high-dose dexamethasone
late night snack and insulin glargine

Conditions: Type 1 Diabetes; Hypoglycemia

Summary: twenty patient with type 1 diabetes, using insulin glargine as basal insulin, participated in a prospective, controlled crossover trial comparing blood glucose profiles over two 24 h periods with and without a late night snack (a slice of rye bread, 20 g carbohydrates, at 10 p.m.), in randomized order. the main endpoint was the number of hypoglycemic episodes with a confirmed laboratory blood glucose ≤ 50 mg/dl between 10 p.m. and 8 p.m. the following day. secondary endpoint was the blood glucose profile during this period.

the order of studies (with and without a late night snack) was determined by randomization. study-related procedures started at 6 p.m. (standard blood glucose profiles with determinations at 6, 8, and 10 p.m, at midnight, at 2, 4, 6:45, 8:45 a.m., and at noon and 2, 6, and 8 p.m. of the following day). at 10 p.m. a late night snack (one slice of whole meal rye bread containing approximately 20 g of carbohydrate) was eaten or no nutrients were consumed, as determined by the randomization protocol. after one day without study-related activities, the study was repeated with the complementary protocol (crossover design). patients were instructed to use fast-acting insulin to correct hyperglycemia three times per day (before major meals) or to take in additional carbohydrate when symptomatic or chemical hypoglycemia was noted. they were asked not to perform strenuous exercise beyond their normal daily activities.

Eligibility criteria:
inclusion criteria: * type 1 diabetes * basal insulin substitution with insulin glargine at least 3 month exclusion criteria: * severe disorders * severe and clinical significant gastroparesis * history of pancreatitis or pancreatic cancer * severe liver disorder (liver enzymes \> three times upper normal limit) * pregnancy * drug- or alcohol abuse

Keywords: hypoglycemia type 1 diabetes
subcision with prp and microneedling versus subcision with saline and micro-needling in treatment of posttraumatic scars

Conditions: Post-Traumatic Scar

Summary: compare different minimally invasive approaches to reach optimum improvement by comparing the efficacy and safety of both combined subcision with platelet-rich plasma and microneedling versus combined subcision with saline and microneedling in the treatment of post-traumatic scars.

the scars at the level of the skin represent a normal and inevitable process of healing traumatic or surgical lesions, but except for the appearance of the skin, they also have a profound psychological impact . thus, people with scars try to integrate them into their sense of self to gain psychological acceptance . many treatment options have been developed for the management of traumatic scars .surgical intervention is an invasive technique, surgery has a high risk of inducing new scar formation . non-surgical approaches for the treatment of traumatic scars include topical treatments and minimally invasive approached as subcision,microneedling and laser. autologous platelet-rich plasma is plasma with a higher concentration of platelets than normally found, it can enhance wound healing which has been demonstrated in controlled studies for soft and hard tissues . the application of autologous platelet-rich plasma to surgical wounds has been shown to accelerate tissue repair and reduce postoperative pain . subcision is a procedure in which a needle is inserted under the skin and passed in multiple directions . although subcision is adequate as a stand-alone treatment, improved results are achieved when it is combined with other modalities. microneedling is a percutaneous collagen induction therapy that causes skin resurfacing. it involves using fine needles to create controlled microdermal injuries starting a complex cascade of growth factors that end in collagen remodeling . because of the different treatment options available for this common problem, the current work aimed to combine and compare different minimally invasive approaches to reach optimum improvement.

Eligibility criteria:
inclusion criteria: * patients with posttraumatic scars * age more than 12 years exclusion criteria: * patients with platelet or blood clotting disorders, and chronic liver or autoimmune diseases. * patients with chronic debilitating diseases, uncontrolled systemic infection, or keloid tendency or with unrealistic expectations. * pregnant females. * patients who did not complete the treatment sessions or the follow-up period.
long-term retinal changes after topical citicoline administration in patients with mild signs of diabetic retinopathy in type 1 diabetes mellitus.

Conditions: Diabetic Retinopathy

Summary: citicoline (cytidine-5'-diphosphocholine) is an essential precursor in the synthesis of phosphatidylcholine, a component of cell membranes. several experimental in vitro and in vivo studies have suggested that citicoline plays a neuroprotective role. a recent clinical study has shown that treatment with topical citicoline induces, after 60 days of therapy, a significant improvement in the ganglion cell function .in addition topical citicoline has been demonstrated in vivo a neuroprotective effect in preventing diabetic retinopathy . the investigators want to evaluate if citicoline may reduce the progression of retinal damage in patients with mild diabetic retinopathy.

the investigators evaluated patients with mild signs of diabetic retinopathy (dr) treated with eye-drop solution with citicoline ( omk2 ophthalmic solution). all patients was randomized in two groups (10:10), one receiving topical administration of omk2 ophthalmic solution for 36 months and one group receiving only the excipients of omk2 (placebo). omk2 ophthalmic solution and the placebo will be used for 36 months three times/day. they will undergo a complete ocular examination at baseline and at 6-, 12-, 18-, 24-, 30- and 36- months after treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of type 1 dm * diagnosis of mild diabetic rethnopathy (dr) * retinal sensitivity impairment evaluated by means of frequency doubling technology (matrix fdt) with a mean deviation (md) p value \<5% or with two locations with p \<5% and one location with p\<1% in the total or pattern deviation plots. exclusion criteria: * hyperopia higher than +5 diopter (d) * myopia higher than -8 d * astigmatism higher than 2 d * visual acuity below 20/25 * significant media opacity * previous ocular surgery * previous diagnosis of glaucoma * uveitis * retinal disease other than mild diabetic retinopathy * patients with any ocular disease * systemic disease other than diabetes * any signs of diabetic retinopathy more advanced than mild as coded by icdrss (e.g. macular edema or any sign of proliferative dr)

Keywords: citicoline neuropathy
bioactive glass in the treatment of enamel white spot lesions

Conditions: White Spot Lesion of Tooth

Summary: the aim of this study is to evaluate the effectiveness of biominf® and novamin® in comparison to casein phosphopeptide-amorphous calcium phosphate (cpp-acp) in the treatment of enamel white spot lesions


Eligibility criteria:
inclusion criteria: * not less than 1 white spot lesion on the labial surface of teeth in the anterior region with code 2 international caries detection and assessment system ii (icdas-ii) or less * absence of any active periodontal disease. * written informed consent exclusion criteria: * known hypersensitivity/allergy to study products and/or materials used * teeth having deep carious lesions or extensive restorations * unwillingness to be randomly assigned to 1 of the 3 treatment groups * advanced periodontal disease.

Keywords: bioactive glass cpp-acp remineralization white spot lesions
real-life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in sweden

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the objective of the current research project is, by using high quality swedish registry data, to evaluate use, tolerance and effect of anti-fibrotic drugs in ipf-patients. secondary study objectives are to determine the clinical profile, determinants of treatment adherence, long-term safety and to describe the patient journey from the first sign of disease to end of treatment.


Eligibility criteria:
inclusion criteria: * all subjects included in the swedish ipf-registry exclusion criteria: * none
effect of micronized creatine monohydrate on muscle mass, strength and performance in older adults submitted to total knee arthroplasty

Conditions: Sarcopenia in Elderly; Frailty at Older Adults; Functional Capacity; Creatine Supplementation; Arthroplasties, Knee Replacement; Physical Performance

Summary: double-blind randomized placebo-controlled clinical trial with two parallel arms. the main objective is to evaluate the efficacy and safety of creatine supplementation in older adults who have been operated on for total knee arthroplasty and undergoing a usual rehabilitation program. the intervention will consist of daily creatine monohydrate supplementation for 12 weeks. the intervention will start after surgery with a loading dose of 20g/day for 1 week and then continue with a maintenance dose of 5g/day for 11 weeks. main outcome mesures included muscle mass, muscle strenght, sarcopenia, frailty, functional capacity and physical performance and will be assessed at baseline, 3 and 6 months follow-up.


Eligibility criteria:
inclusion criteria: * persons 65 years of age or older who have been operated on for the first time for total knee arthroplasty, * who are undergoing an outpatient rehabilitation program according to standard clinical practice, * who sign the informed consent form. exclusion criteria: * chronic renal disease at stage g3b or higher or glomerular filtration rate \<30 ml/min/1.73m2. * hepatic insufficiency, cirrhosis. * neuromuscular and neurodegenerative diseases (amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myasthenia gravis, parkinson's disease, etc.). * severe or very severe chronic obstructive pulmonary disease (copd) (gold iii-iv). * moderate or severe chronic heart failure (nyha 3-4). * central sensitivity syndrome (fibromyalgia and chronic fatigue syndrome). * moderate or severe cognitive impairment (gds≥4). * moderate-severe dependence for basic activities of daily living (preintervention barthel index \<60 points). * hemiparesis, amputation or malformation of any limb. * consumption of creatine monohydrate supplements in the last 6 months.
cardiac magnetic resonance in children with muscular dystrophy

Conditions: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Limb Girdle Muscular Dystrophy

Summary: this protocol will exploit novel state of the art cardiovascular magnetic resonance techniques to examine important changes in the heart in children with muscular dystrophy. the purpose of this study is to compare cardiac magnetic resonance (cmr) with the collected cardiac outcome data obtained in protocol: pitt1109 - cardiac outcome measures in children with muscular dystrophy.


Eligibility criteria:
inclusion criteria: * participant enrolled in the cinrg study: pitt1109 - cardiac outcome measures in children with muscular dystrophy exclusion criteria: * pregnant woman (when uncertain, participants will undergo urine testing) or lactating women * decompensated congestive heart failure (unable to lie flat during cmr) * impaired renal excretory function (calculated glomerular filtration rate less than 30ml/min) * contra-indications to magnetic resonance imaging: * cardiac pacemaker or implantable defibrillator * cerebral aneurysm clip * neural stimulator * metallic ocular foreign body * harrington-rod * any implanted device (i.e. insulin pump, drug infusion device) * claustrophobia * metal shrapnel or bullet

Keywords: cardiac muscle pediatric dystrophy
ultrasound evaluation of crohn's disease

Conditions: Crohn Disease

Summary: the purpose of this study is to assess the effectiveness of a new ultrasound technology for evaluating crohn's disease.

the investigators will study the efficacy of ultrasound shear wave elastography and vascularity imaging for crohn's disease (cd) evaluation. literature evidences demonstrate that bowel stiffness is correlated with fibrosis, while bowel vascularity and perfusion is correlated with inflammation. therefore, the investigators expect the combination of shear wave elastography and vascularity imaging can increase the sensitivity and specificity of cd evaluation. ultrasound is safe, cost-effective, and widely accessible, thus provides an attractive alternative to the clinical standard computed tomography (ct), risks of radiation)) and magnetic resonance imaging (mri), more expensive and limited accessibility)). because ultrasound may not be able to image bowel loops deep in the body, its main role is for follow-up after initial screening by ct or mri, especially for terminal ileum, which is easily accessible by ultrasound and the most frequently affected bowel segment for cd.

Eligibility criteria:
inclusion criteria: - crohn's disease patients with involvement of terminal ileum (thickness \> 3mm). exclusion criteria: * patients with change of medicine or going to surgery over the 6-months follow-up period. * patients with unreliable ultrasound images due to conditions such as large body habitus or poor ultrasound imaging window. * adults lacking capacity to consent. * vulnerable subjects such as prisoners. * pregnant women and nursing mothers. * patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts. * patients with history of hypersensitivity allergic reactions to ultrasound contrast agents.